| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Impel NeuroPharma Inc (NASDAQ: IMPL)
IMPL Technical Analysis
5
| As on 9th Jun 2023 IMPL STOCK Price closed @ 1.27 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 7.04 & Strong Sell for SHORT-TERM with Stoploss of 8.09 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IMPLSTOCK Price
| Open | 1.30 | Change | Price | % |
| High | 1.32 | 1 Day | 0.02 | 1.60 |
| Low | 1.27 | 1 Week | 0.07 | 5.83 |
| Close | 1.27 | 1 Month | -0.45 | -26.16 |
| Volume | 9022 | 1 Year | -7.80 | -86.00 |
| 52 Week High 10.12 | 52 Week Low 0.96 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| IMPL Daily Charts |
IMPL Intraday Charts |
Whats New @ Bazaartrend |
IMPL Free Analysis |
|
|
IMPL Important Levels Intraday
| RESISTANCE | 1.37 |
| RESISTANCE | 1.34 |
| RESISTANCE | 1.32 |
| RESISTANCE | 1.30 |
| SUPPORT | 1.24 |
| SUPPORT | 1.22 |
| SUPPORT | 1.20 |
| SUPPORT | 1.17 |
IMPL Forecast May 2024
| 4th UP Forecast | 7.84 |
| 3rd UP Forecast | 5.73 |
| 2nd UP Forecast | 4.43 |
| 1st UP Forecast | 3.13 |
| 1st DOWN Forecast | -0.59 |
| 2nd DOWN Forecast | -1.89 |
| 3rd DOWN Forecast | -3.19 |
| 4th DOWN Forecast | -5.3 |
IMPL Weekly Forecast
| 4th UP Forecast | 5.07 |
| 3rd UP Forecast | 3.85 |
| 2nd UP Forecast | 3.10 |
| 1st UP Forecast | 2.34 |
| 1st DOWN Forecast | 0.20 |
| 2nd DOWN Forecast | -0.56 |
| 3rd DOWN Forecast | -1.31 |
| 4th DOWN Forecast | -2.53 |
IMPL Forecast2024
| 4th UP Forecast | 20.19 |
| 3rd UP Forecast | 14.12 |
| 2nd UP Forecast | 10.37 |
| 1st UP Forecast | 6.62 |
| 1st DOWN Forecast | -4.08 |
| 2nd DOWN Forecast | -7.83 |
| 3rd DOWN Forecast | -11.58 |
| 4th DOWN Forecast | -17.65 |
Impel NeuroPharma Inc ( NASDAQ USA Symbol : IMPL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IMPL Business Profile
Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington. Address: 201 Elliott Avenue West, Seattle, WA, United States, 98119
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service